US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
US5852041A
(en)
*
|
1993-04-07 |
1998-12-22 |
Sibia Neurosciences, Inc. |
Substituted pyridines useful as modulators of acethylcholine receptors
|
AU4610896A
(en)
*
|
1995-01-06 |
1996-07-24 |
R.J. Reynolds Tobacco Company |
Pharmaceutical compositions for prevention and treatment of central nervous system disorders
|
US5616707A
(en)
*
|
1995-01-06 |
1997-04-01 |
Crooks; Peter A. |
Compounds which are useful for prevention and treatment of central nervous system disorders
|
US5597919A
(en)
*
|
1995-01-06 |
1997-01-28 |
Dull; Gary M. |
Pyrimidinyl or Pyridinyl alkenyl amine compounds
|
US5824692A
(en)
*
|
1995-01-06 |
1998-10-20 |
Lippiello; Patrick Michael |
Pharmaceutical compositions for prevention and treatment of central nervous system disorders
|
US5731314A
(en)
*
|
1995-01-06 |
1998-03-24 |
Bencherif; Merouane |
Pharamceutical compositions for prevention and treatment of tourette's syndrome
|
US5585388A
(en)
*
|
1995-04-07 |
1996-12-17 |
Sibia Neurosciences, Inc. |
Substituted pyridines useful as modulators of acetylcholine receptors
|
US6194581B1
(en)
|
1995-04-07 |
2001-02-27 |
Merck & Co., Inc. |
Substituted pyridines useful as modulators of acetylcholine receptors
|
US5583140A
(en)
*
|
1995-05-17 |
1996-12-10 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of central nervous system disorders
|
US5794887A
(en)
|
1995-11-17 |
1998-08-18 |
Komerath; Narayanan M. |
Stagnation point vortex controller
|
US5616716A
(en)
*
|
1996-01-06 |
1997-04-01 |
Dull; Gary M. |
(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
|
US20020052497A1
(en)
*
|
2000-03-09 |
2002-05-02 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
EP1997806A1
(en)
|
1996-04-23 |
2008-12-03 |
Targacept, Inc. |
Pahrmaceutical compositions for prevention and treatment of central nervous system disorders
|
US6166048A
(en)
*
|
1999-04-20 |
2000-12-26 |
Targacept, Inc. |
Pharmaceutical compositions for inhibition of cytokine production and secretion
|
US6979695B2
(en)
|
1996-04-23 |
2005-12-27 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US5663356A
(en)
*
|
1996-04-23 |
1997-09-02 |
Ruecroft; Graham |
Method for preparation of aryl substituted alefinic secondary amino compounds
|
US5811442A
(en)
*
|
1997-02-21 |
1998-09-22 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
|
US6531606B1
(en)
*
|
1997-02-21 |
2003-03-11 |
Targacept, Inc. |
Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
|
US5861423A
(en)
*
|
1997-02-21 |
1999-01-19 |
Caldwell; William Scott |
Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
|
US7214686B2
(en)
*
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
CA2321991A1
(en)
*
|
1998-02-24 |
1999-09-02 |
Wake Forest University |
Method for the treatment of pain, including chronic and female specific pain
|
KR20010052171A
(ko)
|
1998-04-02 |
2001-06-25 |
알. 제이. 레이놀즈 터베코 컴퍼니 |
의약 조성물 및 그 사용방법
|
US6232316B1
(en)
|
1998-06-16 |
2001-05-15 |
Targacept, Inc. |
Methods for treatment of CNS disorders
|
US20050131034A1
(en)
*
|
1998-06-16 |
2005-06-16 |
Caldwell William S. |
Compounds capable of activating cholinergic receptors
|
US7790757B2
(en)
*
|
1998-06-16 |
2010-09-07 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
US6262124B1
(en)
|
1998-10-22 |
2001-07-17 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
US6953855B2
(en)
*
|
1998-12-11 |
2005-10-11 |
Targacept, Inc. |
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
|
US6432975B1
(en)
|
1998-12-11 |
2002-08-13 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
US20010031771A1
(en)
|
1999-05-24 |
2001-10-18 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
AU5326100A
(en)
*
|
1999-06-07 |
2000-12-28 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
US6455554B1
(en)
|
1999-06-07 |
2002-09-24 |
Targacept, Inc. |
Oxopyridinyl pharmaceutical compositions and methods for use
|
US6890935B2
(en)
*
|
1999-11-01 |
2005-05-10 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
FR2810886B1
(fr)
*
|
2000-06-05 |
2002-12-27 |
Sanjuan Benito Arranz |
Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)
|
US6852741B2
(en)
*
|
2001-12-31 |
2005-02-08 |
University Of Florida |
Compositions and methods for treatment of neurological disorders
|
CA2494506C
(en)
*
|
2002-08-02 |
2009-02-10 |
Nutraceutical Development Corporation |
Development of muscle mass in a mammal
|
AU2004282201A1
(en)
*
|
2003-10-15 |
2005-04-28 |
Targacept, Inc. |
Azabicycyclic compounds for relieving pain and treating central nervous system disorders
|
US7731740B2
(en)
*
|
2004-04-02 |
2010-06-08 |
Arterial Remodelling Technologies, Inc. |
Polymer-based stent assembly
|
EP1802258A4
(en)
|
2004-09-13 |
2015-09-23 |
Chrono Therapeutics Inc |
BIOSYNCHRONE TRANSDERMAL MEDICINES
|
US8252321B2
(en)
|
2004-09-13 |
2012-08-28 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
|
US7459469B2
(en)
*
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
UA88792C2
(ru)
|
2004-11-10 |
2009-11-25 |
Таргасепт, Інк. |
Гидроксибензоатные соли метаникотиновых соединений
|
CN101528698A
(zh)
*
|
2006-05-09 |
2009-09-09 |
阿斯利康公司 |
(2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式
|
TWI389889B
(zh)
*
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
(2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
|
AR062860A1
(es)
*
|
2006-09-15 |
2008-12-10 |
Astrazeneca Ab |
Combinaciones terapeuticas 482
|
US20100028447A1
(en)
*
|
2007-01-22 |
2010-02-04 |
Targacept, Inc. |
Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
|
GB2448224B
(en)
*
|
2007-04-02 |
2010-09-01 |
Parkinson S Inst |
Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
|
JP2010535237A
(ja)
*
|
2007-07-31 |
2010-11-18 |
ターガセプト・インコーポレイテッド |
(2s)−(4e)−n−メチル−5−(3−(5−イソプロポキシピリジン)イル)−4−ペンテン−2−アミンの経皮投与
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
WO2011146009A1
(en)
|
2010-05-20 |
2011-11-24 |
Targacept Inc. |
New process for the preparation of aryl substituted olefinic amines
|
US20130017259A1
(en)
|
2011-07-06 |
2013-01-17 |
The Parkinson's Institute |
Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
|
AU2015258814B2
(en)
*
|
2014-05-16 |
2018-04-05 |
Synaptec Development Llc |
Clearance of amyloid ss
|
US10213586B2
(en)
|
2015-01-28 |
2019-02-26 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
AU2016228779A1
(en)
|
2015-03-12 |
2017-09-07 |
Chrono Therapeutics Inc. |
Craving input and support system
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
WO2018129304A1
(en)
|
2017-01-06 |
2018-07-12 |
Chrono Therapeutics Inc. |
Transdermal drug delivery devices and methods
|
AU2019279884A1
(en)
|
2018-05-29 |
2020-12-10 |
Morningside Venture Investments Limited |
Drug delivery methods and systems
|